Regulatory Affairs
Transatlantic Tariff Siege: EU Pushes US for €150B Exemption List to Protect MedTech and Spirits
As the Turnberry Deal’s 15% tariff baseline takes hold, Brussels has formally requested carve-outs for €150 billion worth of European goods. The stakes are exceptionally high for Ireland’s €13B medical technology industry, where critical components face severe transatlantic margin pressures.
Regulatory Affairs
GEODIS Expands Pharmaceutical Logistics in Poland: Securing Dual GDP and IATA CEIV Pharma Certifications
GEODIS has renewed its IATA CEIV Pharma accreditation in Warsaw and secured GDP certification for its Stryków Dobra contract logistics facility. This dual compliance milestone bolsters Poland’s status as a critical gateway in Europe’s pharmaceutical supply chain.
Biotechnology
Normalization or Correction? Ireland’s Goods Exports Drop 29% in May as Pharma Surplus Narrows
Ireland’s goods exports fell by 29.1% to €16.5 billion in May 2026, driven by a €8 billion drop in pharmaceutical shipments, while imports rose 17.5% to €13.1 billion, narrowing the trade surplus.
Biotechnology
Pilot Photonics Secures €10.4 Million EIC Accelerator Funding to Scale Deeptech Photonic Chips
Dublin-based Pilot Photonics receives up to €10.4 million in EIC Accelerator funding to scale high-volume manufacturing of its patented photonic integrated circuits (PICs) for AI data centres, satellite transceivers, and 6G networks.
Industry
Intel Announces €5 Billion ($5.7 Billion) AI-Driven Semiconductor Expansion at Leixlip, Kildare
Intel has announced a massive €5 billion ($5.7 billion) capital investment at its Leixlip campus in Ireland to expand semiconductor manufacturing capacity, driven by global demand for AI and high-performance computing.
Biotechnology
MGS Mfg. Group Scales Up European Healthcare Manufacturing with 115,000 Sq Ft Leixlip Hub
MGS Mfg. Group completes a major 115,000 sq ft expansion of its Leixlip, Ireland facility, boosting ISO Class 7 and 8 cleanroom capacity, advanced automation, and controlled "whiteroom" environments to meet surging European medical device and pharmaceutical demands.
Regulatory Affairs
Irish EU Council Presidency Prioritizes €10B Biotech Act to Revitalize European Clinical Trials and Sovereign Biomanufacturing
Irish Health Minister Jennifer Carroll MacNeill positions the €10 billion EU Biotech Act as a key priority for Ireland's Council Presidency, aiming to reverse the decline in clinical trials while balancing pharmaceutical incentives against patient access to affordable therapies.
Regulatory Affairs
Addressing the 801-Day Lag: Ireland’s Drug Approval System Demands Urgent Structural Reform
The latest EFPIA Patients W.A.I.T. Indicator report reveals that Irish patients wait an average of 801 days to access newly approved medicines, prompting calls for an overhaul of the HSE and NCPE reimbursement processes and a dedicated mechanism for rare disease orphan drugs.
Industry
Beyond Google: Why B2B Pharma is Adopting 'Search Everywhere' and Generative Engine Optimization (GEO) in 2026
As professional buyers shift from search engines to AI assistants and LinkedIn for vendor research, B2B pharmaceutical and life science companies are pivoting from traditional keyword rankings to "Search Everywhere" and Generative Engine Optimization (GEO).
Industry
University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre
The University of Galway has been chosen to lead the new €64.5 million Research Ireland Rinn Medical Devices Centre as part of a landmark €460 million government investment in seven new national Rinn research centres.
Industry
Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026
Chanelle Pharma has confirmed the renewal of its long-standing partnership with the Galway Races Summer Festival for 2026, marking 41 consecutive years of sponsoring the prestigious Leading Trainer Award alongside the Best Turned Out Series.
Industry
The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape
Ireland's contract manufacturing exports-colloquially known as "phantom exports"-are surging once again, raising fresh questions about the decoupling of headline economic figures from the domestic life sciences economy.